For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Als Therapy Development Institute

USPTO Granted Patents = 17

EPO Patents = 2

Forward Citations = 34

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Fernando G Vieira (13 out of 13 patents)

Steven N Perrin (12 out of 12 patents)

Alan Gill (12 out of 14 patents)

4. John Monteith Lincecum (9 out of 10 patents)

5. Bingbing Jiang (5 out of 5 patents)

6. Cynthia A Gill (5 out of 6 patents)

7. Anna Gill (3 out of 3 patents)

8. Alan Premasiri (3 out of 3 patents)

9. Matvey Lukashev (2 out of 2 patents)

10. Kyle Denton (2 out of 2 patents)

11. Alexey Alexandrovich Lugovskoy (1 out of 50 patents)

12. Alexei Pushechnikov (1 out of 4 patents)

13. Theo Hatzipetros (1 out of 1 patent)

14. Peter Demin (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 12318365 - Inhibition of dipeptide repeat proteins (2025-06-03),

2. 12275793 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2025-04-14),

3. 12157728 - Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions (2024-12-03),

4. 12012422 - Copper complexes for treatment of neurodegenerative disorders (2024-06-18),

5. 11857534 - Inhibition of dipeptide repeat proteins (2024-01-02),

6. 11708349 - Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions (2023-07-25),

7. 11692040 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2023-07-04),

8. 11660324 - Copper complexes for treatment of neurodegenerative disorders (2023-05-30),

9. 11607402 - Inhibition of dipeptide repeat proteins (2023-03-21),

10. 11384152 - Therapeutic anti-CD40 ligand antibodies (2022-07-12),

11. 11014990 - Anti-CD40L antibodies (2021-05-25),

12. 10683356 - Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies (2020-06-16),

13. 10106618 - Anti-CD40L antibodies (2018-10-23),

14. 9044459 - Method for the treatment of neurodegenerative diseases (2015-06-02),

15. 8946301 - Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis (2015-02-03),

The ALS Therapy Development Institute (ALS TDI) is a nonprofit biotech focused on accelerating the discovery and development of treatments for amyotrophic lateral sclerosis (ALS). As the world's foremost drug discovery center solely dedicated to ALS research, ALS TDI actively partners with academia, industry, and government organizations to collaborate and advance potential therapies. Through its innovative Precision Medicine Program, ALS TDI uses cutting-edge research tools and techniques to develop personalized treatments for people living with ALS.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#129 in Cambridge, MA

#1,106 in Massachusetts

#18,330 in US

#34,858 in the World

Cambridge, MA, United States of America

Als Therapy Development Institute

Forward Citations = 34

14 inventors:

Fernando G Vieira (13 out of 13 patents)

Steven N Perrin (12 out of 12 patents)

Alan Gill (12 out of 14 patents)

4. John Monteith Lincecum (9 out of 10 patents)

5. Bingbing Jiang (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…